AI Platform Could Improve Prostate Cancer Drug Therapy

A new research model identified compounds that may help overcome prostate cancer treatment resistance.

Updated on Oct. 21, 2026 in Cancer

A close-up of a glass chemical vessel on a laboratory workbench, representing research into new medical treatments. — UCLA researchers developed the MAESTRO AI platform to identify drug combinations, potentially overcoming treatment resistance in prostate cancer patients. AI Illustration. Upload story photo >

Live Poll

Do you trust artificial intelligence to accelerate the discovery of effective medical treatments?

UCLA researchers have developed an artificial intelligence platform called MAESTRO to identify drug combinations that may improve prostate cancer treatment. The system recently identified berberine as a potential compound to enhance the effectiveness of enzalutamide, a finding that could help address treatment resistance.

Why it matters

Prostate cancer cells often develop resistance by activating alternative pathways when standard androgen receptor treatments are blocked. Using AI to scan thousands of compounds may provide a faster way to find new, synergistic treatments that bypass these survival mechanisms.

In a preclinical study, the MAESTRO platform screened 3,592 natural products and identified 23 compounds that showed synergy with enzalutamide in 4 prostate cancer models. These findings are considered preliminary as the system is still being refined for broader use.

The players

UCLA

A Los Angeles-based research university that conducted the study on the MAESTRO artificial intelligence platform.

The details

The MAESTRO platform uses large language models to analyze vast amounts of scientific knowledge regarding drug mechanisms and cancer cell pathways. By evaluating each candidate over 100 times to rank consistency, the system predicted that berberine could enhance the activity of AMPK while suppressing mTORC1 signaling. This mechanism may help disrupt the alternative survival pathways that prostate cancer cells use to evade traditional enzalutamide treatments.

UCLA researchers announced the development of the MAESTRO platform in October 2026.

Health Landscape

This research updates the ongoing efforts of the UCLA prostate cancer research program to overcome drug resistance through computational modeling. It marks a shift toward using artificial intelligence to accelerate the discovery of synergistic compounds in oncology.

This development is currently in the preclinical stage and does not change existing treatment plans for patients. If you are managing prostate cancer and have concerns about treatment resistance, this is a topic worth discussing with your physician during your next appointment.

The takeaway

The use of artificial intelligence to identify new drug combinations offers a promising way to target cancer cell resistance. While the MAESTRO results are preliminary, patients should continue to follow established treatment protocols and speak with their oncologist about any new clinical developments.